Immunocore Holdings (Immunocore Holdings) Accounts Payable & Accrued Expense : $188.7 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Accounts Payable & Accrued Expense?

Immunocore Holdings's quarterly accounts payable & accrued expense increased from Sep. 2023 ($115.2 Mil) to Dec. 2023 ($159.5 Mil) and increased from Dec. 2023 ($159.5 Mil) to Mar. 2024 ($188.7 Mil).

Immunocore Holdings's annual accounts payable & accrued expense increased from Dec. 2021 ($47.1 Mil) to Dec. 2022 ($99.9 Mil) and increased from Dec. 2022 ($99.9 Mil) to Dec. 2023 ($159.5 Mil).

Immunocore Holdings Accounts Payable & Accrued Expense Historical Data

The historical data trend for Immunocore Holdings's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Accounts Payable & Accrued Expense Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

38.76

34.58

47.09

99.94

159.54

Immunocore Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															94.58	108.79	115.19	159.54	188.72

Immunocore Holdings Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Immunocore Holdings (Immunocore Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

6YG:Germany 6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.